Ranbaxy Labs marks 20th year in Ukraine
GURGAON, India — Ranbaxy Labs is celebrating the 20th anniversary of its operations in Ukraine, the Indian generic drug maker said Wednesday.
The drug maker established a base in the eastern European country in 1993 and has since become the largest drug company in the market, whose value is estimated at $3.7 billion, according to the company. Ranbaxy’s products in Ukraine include branded and generic drugs.
"Ranbaxy has been providing high-quality, affordable generic medicines to the citizens of Ukraine for the last two decades, thereby supporting the government to bring down healthcare costs," Ranbaxy CEO and managing director Arun Sawhney said. "We remain committed to the Ukraine market and its people and will continue to operate for our paradigm of quality and patients first."
Perrigo seeks approval for generic version of Acanya
ALLEGAN, Mich. — Drug maker Perrigo has filed with the Food and Drug Administration for approval of a generic topical ointment for treating acne in adolescents and adults, the company said Wednesday.
Perrigo said it filed for approval of clindamycin phosphate and benzoyl peroxide gel in the 1.2%/2.5% strengths. The drug is used to treat acne in patients 12 years and older.
The drug is a generic version of Dow Pharmasciences’ Acanya gel, which has annual sales of about $122 million, according to Symphony Health Solutions. Perrigo said it notified Dow of the filing, to which Dow responded by filing suit against Perrigo in the U.S. District Court for the District of New Jersey, alleging patent infringement. Under the Hatch-Waxman Act of 1984, the suit puts an automatic stay of FDA approval on Perrigo’s product for 30 months, or until the companies settle the case.
Unilife, Hikma enter $40 million partnership
YORK, Pa. — Unilife Corp. has entered a deal with Hikma to launch 20 generic injectable drugs using Unilife’s pre-filled syringe technology, the two companies said Wednesday.
Under the 15-year agreement, Unilife will supply Hikma with its platform, including the Unifill syringe and the Unifill Nexus. Hikma has selected an initial list of 20 generic injectable products that it will include in the deal.
Under the deal, Hikma will pay Unilife $40 million, including $5 million upfront, $15 million in 2014 and $20 million in 2015.
"This agreement supports our strategy of developing higher-value products, and we are extremely pleased to be partnering with Unilife to develop our generic injectables capabilities," Hikma CEO Said Darwazah said. "We look forward to leveraging Unilife’s innovative platform of Unifill syringes to differentiate our injectable products and to increase our market share."